中医药治疗原发性肝癌的切入点与难点

钊梦媛; 张国梁

doi:10.3969/j.issn.1001-5256.2021.09.004

中医药治疗原发性肝癌的切入点与难点

DOI: 10.3969/j.issn.1001-5256.2021.09.004

钊梦媛,
张国梁^,

安徽中医药大学第一附属医院感染科，合肥 230031

基金项目:

国家自然科学基金 (81874451)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：钊梦媛负责数据收集，资料分析，论文撰写；张国梁负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
张国梁，zhangguoliang61@sina.com

中图分类号: R735.7
计量
- 文章访问数: 697
- HTML全文浏览量: 350
- PDF下载量: 98
- 被引次数: 0
出版历程
- 收稿日期: 2021-04-30
- 录用日期: 2021-04-30
- 出版日期: 2021-09-20

Breakthrough points and difficulties in traditional Chinese medicine treatment of primary liver cancer

Mengyuan ZHAO,
Guoliang ZHANG^,

Department of Infectious Diseases, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, China

Research funding:

National Natural Science Foundation of China (81874451)

摘要

摘要: 原发性肝癌是我国常见的恶性肿瘤之一，大多数发现时已经是中晚期，生存期短，预后差。近年来，中医药在原发性肝癌的防治方面展现了其独特的优势，在改善肝癌患者的生存质量、增强免疫力、延长生命等方面有着显著疗效。就原发性肝癌的中西医治疗现状进行了综述，结合临床治疗特点提出中医药治疗的切入点与难点，以期为临床治疗原发性肝癌提供一定的参考。
- 肝肿瘤 /
- 中药疗法 /
- 中西医结合疗法
Abstract: Primary liver cancer is one of the most common malignant tumors in China, and most patients are in the advanced stage at the time of diagnosis, with a short survival time and poor prognosis. In recent years, traditional Chinese medicine has shown its unique advantages in the prevention and treatment of primary liver cancer and has achieved a marked clinical effect in improving quality of life, enhancing immunity, and prolonging the life of patients with liver cancer. This article reviews the current status of traditional Chinese medicine and Western medicine in the treatment of primary liver cancer and proposes the breakthrough points and difficulties in traditional Chinese medicine treatment based on the features of clinical treatment, in order to provide a reference for the clinical treatment of primary liver cancer.
- Liver Neoplasms /
- Drug Therapy (TCD) /
- TCM WM THERAPY

HTML全文

参考文献(64)

[1]	TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262.
[2]	CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[3]	ZHOU J, SUN HC, WANG Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition)[J]. Liver Cancer, 2018, 7(3): 235-260. DOI: 10.1159/000488035.
[4]	OUSSALAH A, AVOGBE PH, GUYOT E, et al. BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease[J]. Oncotarget, 2017, 8(38): 62842-62857. DOI: 10.18632/oncotarget.11327.
[5]	LI T, SUN CJ, ZHANG L. Diagnostic value of combined detection of serum ferritin and alpha fetoprotein in primary liver cancer[J]. Contemp Med, 2021, 27(4): 38-40. DOI: 10.3969/j.issn.1009-4393.2021.04.013. 李彤, 孙长俭, 张乐. 血清铁蛋白和甲胎蛋白联合检测原发性肝癌的诊断分析[J]. 当代医学, 2021, 27(4): 38-40. DOI: 10.3969/j.issn.1009-4393.2021.04.013.
[6]	SINGAL AG, LAMPERTICO P, NAHON P. Epidemiology and surveillance for hepatocellular carcinoma: New trends[J]. J Hepatol, 2020, 72(2): 250-261. DOI: 10.1016/j.jhep.2019.08.025.
[7]	QIAN XJ, QU CF, LU FM. The indispensable role of liver cancer markers in ultrasound screening and monitoring of early-stage hepatocellular carcinoma[J]. Chin Hepatol, 2019, 24(8): 851-853. DOI: 10.3969/j.issn.1008-1704.2019.08.003. 钱相君, 曲春枫, 鲁凤民. 肝癌肿瘤标记物在超声筛查监测早期肝细胞癌中的作用不可或缺[J]. 肝脏, 2019, 24(8): 851-853. DOI: 10.3969/j.issn.1008-1704.2019.08.003.
[8]	MA YF, SU X, YANG Y, et al. Experience of YU rencun treating primary liver cancer[J]. Liaoning J Tradit Chin Med, 2017, 44(12): 2505-2506. DOI: 10.13192/j.issn.1000-1719.2017.12.011. 马云飞, 孙旭, 杨永, 等. 名老中医郁仁存治疗原发性肝癌经验拾萃[J]. 辽宁中医杂志, 2017, 44(12): 2505-2506. DOI: 10.13192/j.issn.1000-1719.2017.12.011.
[9]	JI XZ, ZHOU MH, LIU ZD, et al. Wu Yusheng's experience in the syndrome differentiation-based treatment of liver cancer[J]. Zhejiang J Integr Tradit Chin West Med, 2019, 29(1): 2-5. DOI: 10.3969/j.issn.1005-4561.2019.01.002. 季兴祖, 周敏华, 刘忠达, 等. 吴玉生辨治肝癌经验[J]. 浙江中西医结合杂志, 2019, 29(1): 2-5. DOI: 10.3969/j.issn.1005-4561.2019.01.002.
[10]	SHAO QW, ZHANG LZ. Professor Shao Mengyang's academic experience in the treatment of primary liver cancer[J]. Lishizhen Med Mater Med Res, 2018, 29(8): 1996-1997. DOI: 10.3969/j.issn.1008-0805.2018.08.072. 邵清蔚, 张良芝. 邵梦扬教授治疗原发性肝癌学术经验[J]. 时珍国医国药, 2018, 29(8): 1996-1997. DOI: 10.3969/j.issn.1008-0805.2018.08.072.
[11]	RUAN QF, KANG MR, KANG SQ. Experience of Prof. KANG Liang-shi for treating primary liver cancer[J]. Clin J Chin Med, 2014, 6(20): 71-72. DOI: 10.3969/j.issn.1674-7860.2014.20.040. 阮清发, 康旻睿, 康素琼. 康良石教授治疗原发性肝癌经验总结[J]. 中医临床研究, 2014, 6(20): 71-72. DOI: 10.3969/j.issn.1674-7860.2014.20.040.
[12]	LI JY, LI XH, ZHANG Y, et al. Syndrome differentiation-based treatment of primary liver cancer developed by Professor Qian Ying: An analysis of experience[J]. J Clin Hepatol, 2016, 32(7): 1342-1344. DOI: 10.3969/j.issn.1001-5256.2016.07.026. 李晶滢, 李秀惠, 张寅, 等. 钱英教授辨治原发性肝癌的经验探析[J]. 临床肝胆病杂志, 2016, 32(7): 1342-1344. DOI: 10.3969/j.issn.1001-5256.2016.07.026.
[13]	LEE K, LEE KB, YI NJ, et al. Prognosis of hepatocellular carcinoma after liver transplantation: comparative analysis with partial hepatectomy[J]. J Pathol Translat Med, 2017, 51(1): 79-86. DOI: 10.4132/jptm.2016.10.13.
[14]	SMOLOCK AR, CRISTESCU MM, HINSHAW A, et al. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone[J]. Abdom Radiol (NY), 2018, 43(9): 2497-2504. DOI: 10.1007/s00261-018-1464-9.
[15]	ZHAO G, ZHANG CY, LI SW, et al. Clinical effect of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization in treatment of liver cancer[J]. Capit Food Med, 2020, 27(13): 34-35. DOI: 10.3969/j.issn.1005-8257.2020.13.021. 赵刚, 张朝阳, 李胜伟, 等. 射频消融术(PRFA)与TACE联合PRFA综合治疗肝癌的临床疗效比较[J]. 首都食品与医药, 2020, 27(13): 34-35. DOI: 10.3969/j.issn.1005-8257.2020.13.021.
[16]	Precise Radiotherapy Study Group, Chinese Society of Liver Cancer, Chinese Medical Doctor Association; Liver Cancer Study Group, Committee of Radiation Oncology, Chinese Research Hospital Association; Committee of Tumor Radiobiology and Multimodal Imaging and Therapy, Chinese Research Hospital Association, et al. Consensus on radiation therapy for primary liver cancer (2020)[J]. J Clin Hepatol, 2021, 37(2): 296-301. DOI: 10.3969/j.issn.1001-5256.2021.02.010. 中国医师协会肝癌专业委员会精确放疗学组, 中国研究型医院学会放射肿瘤学专业委员会肝癌学组, 中国研究型医院学会肿瘤放射生物与多模态诊疗专业委员会, 等. 原发性肝癌放射治疗专家共识(2020年版)[J]. 临床肝胆病杂志, 2021, 37(2): 296-301. DOI: 10.3969/j.issn.1001-5256.2021.02.010.
[17]	SUN Y. New Milestone in the development of clinical oncology—molecular targeted therapy[J]. Anti-Tumor Pharm, 2011, 1(1): 1-5. DOI: 10.3969/j.issn.2095-1264.2011.01.001. 孙燕. 肿瘤治疗的新里程碑——靶向药物治疗[J]. 肿瘤药学, 2011, 1(1): 1-5. DOI: 10.3969/j.issn.2095-1264.2011.01.001.
[18]	LIN Z, YANG WS, YIN KN. Expression of PD-L1 protein in primary hepatocarcinoma and its significance in immunotherapy[J]. Pract J Cancer, 2021, 36(1): 69-71. DOI: 10.3969/j.issn.1001-5930.2021.01.018. 林蓁, 杨文圣, 尹可能. 原发性肝细胞肝癌PD-L1蛋白表达及在免疫治疗中的意义[J]. 实用癌症杂志, 2021, 36(1): 69-71. DOI: 10.3969/j.issn.1001-5930.2021.01.018.
[19]	PARDOLL DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264. DOI: 10.1038/nrc3239.
[20]	DU XY. Pan Minqiu's experience in the treatment of primary liver cancer[J]. Hunan J Tradit Chin Med, 2014, 30(11): 23-25. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZO201411011.htm 杜小艳. 潘敏求治疗原发性肝癌经验[J]. 湖南中医杂志, 2014, 30(11): 23-25. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZO201411011.htm
[21]	SHE B, CHEN Y, ZHANG RM. Exploration into professor Zhang Ruiming's clinical experience of treating primary liver cancer[J]. Western J Traditl Chin Med, 2018, 31(1): 30-34. DOI: 10.3969/j.issn.1004-6852.2018.01.010. 佘彬, 陈雁, 张瑞明. 张瑞明教授治疗原发性肝癌临床经验初探[J]. 西部中医药, 2018, 31(1): 30-34. DOI: 10.3969/j.issn.1004-6852.2018.01.010.
[22]	GENG YQ. Zhang Yonghong's experience in the treatment of primary liver cancer[J]. Jiangsu J Traditi Chin Med, 2016, 48(6): 21-22, 25. https://www.cnki.com.cn/Article/CJFDTOTAL-JSZY201606008.htm 耿雨晴. 章永红治疗原发性肝癌经验辑要[J]. 江苏中医药, 2016, 48(6): 21-22, 25. https://www.cnki.com.cn/Article/CJFDTOTAL-JSZY201606008.htm
[23]	WANG JS, CHEN LY, LIU YQ, et al. Professor SUN Guizhi's experience in treating liver cancer from tonifying the spleen and stomach, and preventive treatment of disease[J]. J Tradit Chin Med, 2015, 56(13): 1096-1098. DOI: 10.13288/j.11-2166/r.2015.13.005. 王靖思, 陈兰羽, 刘玉琴, 等. 孙桂芝从补脾胃、治未病论治肝癌经验[J]. 中医杂志, 2015, 56(13): 1096-1098. DOI: 10.13288/j.11-2166/r.2015.13.005.
[24]	PAN CF, SHEN KP. Professor Qiu Jiaxin's academic experience in the treatment of liver cancer[J]. Shanxi J Tradit Chin Med, 2017, 33(6): 8-9, 22. https://www.cnki.com.cn/Article/CJFDTOTAL-SHIX201706004.htm 潘传芳, 沈克平. 邱佳信教授治疗肝癌学术经验[J]. 山西中医, 2017, 33(6): 8-9, 22. https://www.cnki.com.cn/Article/CJFDTOTAL-SHIX201706004.htm
[25]	FAN HF, LI DH, HUO BJ, et al. Professor Liu Yaxian's experience in the syndrome differentiation-based treatment of liver cancer[J]. Global Tradit Chin Med, 2018, 11(1): 88-90. DOI: 10.3969/j.issn.1674-1749.2018.01.024. 范焕芳, 李德辉, 霍炳杰, 等. 刘亚娴教授辨证论治肝癌经验总结[J]. 环球中医药, 2018, 11(1): 88-90. DOI: 10.3969/j.issn.1674-1749.2018.01.024.
[26]	WANG L, ZHOU RY. ZHOU Rongyao's experience in treating primary liver cancer with reinforcing kidney and invigorating spleen[J]. Liaoning J Tradit Chin Med, 2014, 41(12): 2547-2548. DOI: 10.13192/j.issn.1000-1719.2014.12.014. 王磊, 周荣耀. 周荣耀补肾健脾法治疗原发性肝癌经验[J]. 辽宁中医杂志, 2014, 41(12): 2547-2548. DOI: 10.13192/j.issn.1000-1719.2014.12.014.
[27]	YU HY, JIANG JM, XIONG Y. Professor Xiong Yan's clinical experience in treatment of primary liver cancer[J]. Asia-Pacific Tradit Med, 2021, 17(1): 103-104. DOI: 10.11954/ytctyy.202101034. 俞宏燕, 蒋佳敏, 熊焰. 熊焰教授治疗原发性肝癌经验[J]. 亚太传统医药, 2021, 17(1): 103-104. DOI: 10.11954/ytctyy.202101034.
[28]	WANG JY, ZHAO Y, WANG LT. Professor Wang Lingtai's experience in treating primary liver cancer[J]. Shanghai J Tradit Chin Med, 2010, 44(2): 20-21. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ201002010.htm 王见义, 赵莹, 王灵台. 王灵台治疗原发性肝癌经验探微[J]. 上海中医药杂志, 2010, 44(2): 20-21. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ201002010.htm
[29]	ZHOU B, LIANG YJ. Professor Zhou Daihan's experience in the differentiation and treatment of liver cancer based on disease, syndrome, and symptom[J]. J New Chin Med, 2011, 43(8): 185-186. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201108096.htm 周蓓, 梁艳菊. 周岱翰教授病证症结合辨治原发性肝癌经验简介[J]. 新中医, 2011, 43(8): 185-186. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201108096.htm
[30]	ZHAI XF, CHEN Z, LI B, et al. Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: A multicenter randomized controlled trial[J]. J Integr Med, 2013, 11(2): 90-100. DOI: 10.3736/jintegrmed2013021.
[31]	SUN Z, CUI J, ZHU Y, et al. Traditional Chinese Medicine in improving overall survival rates for small hepatocellular carcinoma after resection: A retrospective cohort study[J]. J Liaoning Univ Tradit Chin Med, 2014, 16(12): 63-66. DOI: 10.13194/j.issn.1673-842x.2014.12.025. 孙振, 崔珺, 朱役, 等. 中医药综合方案提高根治术后小肝癌患者生存率回顾性队列研究[J]. 辽宁中医药大学学报, 2014, 16(12): 63-66. DOI: 10.13194/j.issn.1673-842x.2014.12.025.
[32]	CHEN W. Cancer statistics: Updated cancer burden in China[J]. Chin J Cancer Res, 2015, 27(1): 1. DOI: 10.3978/j.issn.1000-9604.2015.02.07.
[33]	GUO F. Observation on the curative effect of Traditional Chinese Medicine adjuvant therapy for primary liver cancer after operation[J]. Guangming J Chin Med, 2020, 35(18): 2855-2856. DOI: 10.3969/j.issn.1003-8914.2020.18.024. 郭风. 中药辅助治疗原发性肝癌术后临床观察[J]. 光明中医, 2020, 35(18): 2855-2856. DOI: 10.3969/j.issn.1003-8914.2020.18.024.
[34]	CHEN Y, WANG MQ, SONG W, et al. Retrospective cohort study on the effect of comprehensive treatment of Chinese medicine on the survival of patients with advanced hepatocellular carcinoma[J]. J Hepatobiliary Surg, 2018, 26(4): 292-296. DOI: 10.3969/j.issn.1006-4761.2018.04.017. 陈杨, 汪名权, 宋文, 等. 中医药联合TACE对中晚期肝癌患者生存期影响的回顾性队列研究[J]. 肝胆外科杂志, 2018, 26(4): 292-296. DOI: 10.3969/j.issn.1006-4761.2018.04.017.
[35]	SUN DX, LEI T, ZHOU J. Clinical effect of Lidan decoction combined with magnesium isoglycyrrhizinate in treatment of liver injury after radiofrequency ablation for liver cancer: An analysis of 26 cases[J]. Mod Tradit Chin Med, 2018, 38(1): 29-30. DOI: 10.13424/j.cnki.mtcm.2018.01.011. 孙东旭, 雷霆, 周军. 利胆汤联合异甘草酸镁治疗肝癌射频消融术后肝损伤26例[J]. 现代中医药, 2018, 38(1): 29-30. DOI: 10.13424/j.cnki.mtcm.2018.01.011.
[36]	ZHANG HY, WANG HB. Clinical effect of radiofrequency ablation combined with Jiawei Sijunzi decoction in treatment of primary liver cancer[J]. J Pract Tradit Chin Med, 2019, 35(5): 549-550. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYAO201905034.htm 张厚云, 王洪白. 射频消融术结合加味四君子汤治疗原发性肝癌临床观察[J]. 实用中医药杂志, 2019, 35(5): 549-550. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYAO201905034.htm
[37]	ZHONG JH, MA L, LI LQ. Postoperative therapy options for hepatocellular carcinoma[J]. Scand J Gastroenterol, 2014, 49(6): 649-661. DOI: 10.3109/00365521.2014.905626.
[38]	AN P, LI XY, CAI ZM, et al. Study on the mechanism of enhancing the sensitivity of baicalein to radiotherapy of hepatoma cell line HepG2[J]. Shaanxi J Tradit Chin Med, 2018, 39(2): 150-153. DOI: 10.3969/j.issn.1000-7369.2018.02.004. 安鹏, 李星瑶, 蔡子墨, 等. 黄芩素对肝癌细胞HepG2放疗增敏作用的机制研究[J]. 陕西中医, 2018, 39(2): 150-153. DOI: 10.3969/j.issn.1000-7369.2018.02.004.
[39]	SHI XR, ZHANG KM, XU XY. Effects of Yiqi Huoxue Herbs on liver microcirculation and hepatic fibrosis indexes for primary liver cancer after radiotherapy[J]. World Chin Med, 2018, 13(5): 1123-1126. DOI: 10.3969/j.issn.1673-7202.2018.05.018. 石相如, 章凯敏, 徐晓娅. 益气活血中药对肝癌放疗后肝脏微循环及肝纤维化指标的影响[J]. 世界中医药, 2018, 13(5): 1123-1126. DOI: 10.3969/j.issn.1673-7202.2018.05.018.
[40]	WANG Y. Effect and safety of modified Gexia Zhuyu decoction on chemotherapeutic efficacy in patients with liver cancer with Qi stagnation and blood stasis[J]. Inner Mongolia J Tradit Chin Med, 2018, 50(12): 1484-1485. DOI: 10.16096/J.cnki.nmgyxzz.2018.50.12.038. 王莹. 膈下逐瘀汤加减对肝癌(气滞血瘀型)患者化疗效果的影响及安全性探讨[J]. 内蒙古医学杂志, 2018, 50(12): 1484-1485. DOI: 10.16096/J.cnki.nmgyxzz.2018.50.12.038.
[41]	WU JY, ZHU Y. Clinical effect of modified Longdan Xiegan decoction combined with chemotherapy in treatment of primary liver cancer with damp-heat retention[J]. J Chin Med Materls, 2014, 37(7): 1301-1304. DOI: 10.13863/j.issn1001-4454.2014.07.052. 吴菊意, 朱云. 龙胆泻肝汤加减联合化疗治疗湿热内阻型原发性肝癌临床观察[J]. 中药材, 2014, 37(7): 1301-1304. DOI: 10.13863/j.issn1001-4454.2014.07.052.
[42]	ZHAO H. Efficacy of Sijunzi Decoction combined with raltitrexed and oxaliplatin in the treatment of advanced liver cancer and its effect on immune function[J]. Mod J Integr Tradit Chin West Med, 2019, 28(15): 1630-1633, 1644. DOI: 10.3969/j.issn.1008-8849.2019.15.009. 赵华. 四君子汤联合雷替曲塞和奥沙利铂治疗晚期肝癌的疗效及对免疫功能的影响[J]. 现代中西医结合杂志, 2019, 28(15): 1630-1633, 1644. DOI: 10.3969/j.issn.1008-8849.2019.15.009.
[43]	TANG YF, ZHU XJ, HUANG LY, et al. Clinical study on Huaier Granules combined with sorafenib in treatment of advanced liver cancer[J]. Drugs Clinic, 2018, 33(7): 1732-1735. DOI: 10.7501/j.issn.1674-5515.2018.07.039. 唐亦非, 朱晓骏, 黄凌鹰, 等. 槐耳颗粒联合索拉非尼治疗晚期肝癌的临床研究[J]. 现代药物与临床, 2018, 33(7): 1732-1735. DOI: 10.7501/j.issn.1674-5515.2018.07.039.
[44]	LIU JP, CAO JG, YUAN CJ, et al. Evaluation of therapeutic effect of Qinghuo Tongluo prescription combined with sorafenib on liver cancer based on"Image Thinking"[J]. J Hubei Univ Chin Med, 2018, 20(5): 22-25. DOI: 10.3969/j.issn.1008-987x.2018.05.05. 刘娇萍, 曹继刚, 袁昌劲, 等. 基于"象思维"的清火通络方联合索拉非尼治疗肝癌疗效评价[J]. 湖北中医药大学学报, 2018, 20(5): 22-25. DOI: 10.3969/j.issn.1008-987x.2018.05.05.
[45]	ZHANG XX, LONG SQ, YANG XB, et al. Efficacy of Jianpi Liqi Yiliu Formula combined with CIK treatment on the immune function and quality of life in patients with advanced hepatocellular carcinoma[J]. Guangdong Med J, 2016, 37(3): 441-444. https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX201603044.htm 张晓轩, 龙顺钦, 杨小兵, 等. 健脾理气抑瘤方联合CIK治疗对晚期肝细胞癌患者免疫功能及生活质量的影响[J]. 广东医学, 2016, 37(3): 441-444. https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX201603044.htm
[46]	DANG ZB, YAN J, LI LR, et al. Clinical efficacy of Huaier granule in the treatment of HBV related primary liver cancer[J]. Chin J Integr Trad West Med Dig, 2020, 28(9): 681-687. DOI: 10.3969/j.issn.1671-038X.2020.09.08. 党志博, 晏军, 李玲孺, 等. 槐耳颗粒治疗乙肝相关原发性肝癌的临床疗效分析[J]. 中国中西医结合消化杂志, 2020, 28(9): 681-687. DOI: 10.3969/j.issn.1671-038X.2020.09.08.
[47]	GAO YR, CHEN SJ, HOU YW, et al. Clinical effect of Huaier Granule sequential with radiofrequency ablation and TACE in treating primary hepatic carcinoma[J]. J Changchun Univ Chin Med, 2020, 36(4): 684-687. DOI: 10.13463/j.cnki.cczyy.2020.04.021. 高远韧, 陈思佳, 侯英文, 等. TACE联合射频消融术序贯槐耳颗粒治疗原发性肝癌[J]. 长春中医药大学学报, 2020, 36(4): 684-687. DOI: 10.13463/j.cnki.cczyy.2020.04.021.
[48]	NIU T, ZHAO L, LIN X, et al. Cinobufagin, a bufadienolide from traditional Chinese medicine Bufo bufo gargarizans CANTOR, inhibits PC3 cell growth in vitro and in vivo[J]. J Trad Chin Med Sci, 2019, 6(2): 175-183. http://qikan.cqvip.com/Qikan/Article/Detail?id=00045F8O5X50CH50MPDG0JP0MPDG9
[49]	WU D, ZHOU WY, LIN XT, et al. Bufalin induces apoptosis via mitochondrial ROS-mediated caspase-3 activation in HCT-116 and SW620 human colon cancer cells[J]. Drug Chem Toxicol, 2019, 42(4): 444-450. DOI: 10.1080/01480545.2018.1512611.
[50]	SHEN TB, ZHANG W, CHEN Y, et al. Clinical observation of cinobufacini capsule in the Treatment of primary Hepatocellular carcinoma[J]. Chin J Integr Trad West Med Dig, 2019, 29(2): 124-126, 142. DOI: 10.3969/j.issn.1005-0264.2019.02.009. 沈天白, 张玮, 陈阳, 等. 华蟾素胶囊辅助治疗原发性肝癌的临床研究[J]. 中西医结合肝病杂志, 2019, 29(2): 124-126, 142. DOI: 10.3969/j.issn.1005-0264.2019.02.009.
[51]	LI XY, WANG QM, DENG XS, et al. Clinical effect of hepatic arterial infusion with Brucea javanica oil emulsion injection combined with lipiodol embolization in treatment of advanced primary liver cancer[J]. Hunan J Tradit Chin Med, 2020, 36(8): 5-7, 17. DOI: 10.16808/j.cnki.issn1003-7705.2020.08.002. 李欣依, 王其美, 邓湘生, 等. 经肝动脉灌注鸦胆子油乳注射液联合碘油栓塞治疗中晚期原发性肝癌的临床研究[J]. 湖南中医杂志, 2020, 36(8): 5-7, 17. DOI: 10.16808/j.cnki.issn1003-7705.2020.08.002.
[52]	LI LH, TIAN JM. Effect of Kang'ai injection on immune function in patients with advanced primary liver cancer after interventional surgery[J]. Nei Mongol J Tradit Chin Med, 2016, 35(2): 105-106. DOI: 10.3969/j.issn.1006-0979.2016.02.104. 李琳慧, 田劲猛. 康艾注射液对介入手术后晚期原发性肝癌患者免疫功能的影响[J]. 内蒙古中医药, 2016, 35(2): 105-106. DOI: 10.3969/j.issn.1006-0979.2016.02.104.
[53]	ZENG JZ, YANG Q, XIE RJ, et al. Curative effect of compound kushen injection on primary liver cancer with liver injury and cancer pain[J]. J Guzhou Med Univ, 2021, 46(1): 67-71. DOI: 10.19367/j.cnki.2096-8388.2021.01.012. 曾经章, 杨勤, 谢汝佳, 等. 复方苦参注射液对原发性肝癌合并肝损伤和癌性疼痛的治疗效果[J]. 贵州医科大学学报, 2021, 46(1): 67-71. DOI: 10.19367/j.cnki.2096-8388.2021.01.012.
[54]	China Association of Chinese Medicine. Response evaluation criteria for traditional Chinese medicine treatment of liver cancer (draft version)[C]//Collected papers from the 2012 Academic Annual Conference on Traditional Chinese Medicine Prevention and Treatment of Tumors by China Association of Chinese Medicine, 2012: 699-706. 中华中医药学会. 肝癌中医临床疗效评价标准(草案)[C]//中华中医药学会2012年中医药防治肿瘤学术年会论文集, 2012: 699-706.
[55]	LIU XY, GONG YX. Thoughts and methods for evaluating the clinical effect of traditional Chinese medicine[J]. Diet Health, 2020, 7(15): 71-72. https://www.cnki.com.cn/Article/CJFDTOTAL-XBZX200503004.htm 刘昕烨, 巩雅欣. 中医临床疗效评价的思路与方法探讨[J]. 饮食保健, 2020, 7(15): 71-72. https://www.cnki.com.cn/Article/CJFDTOTAL-XBZX200503004.htm
[56]	LIU JP. Modality of combined methods of quantitative and qualitative research in evaluation of therapeutic effects of chinese medicine[J]. Chin J Integr Trad West Med, 2011, 31(5): 581-586. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201105002.htm 刘建平. 定量与定性研究方法相结合的中医临床疗效评价模式[J]. 中国中西医结合杂志, 2011, 31(5): 581-586. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201105002.htm
[57]	PANG L, GE XG. Analysis of "Survival with Tumor" idea in traditional chinese medicine oncology[J]. J Tradit Chin Med, 2018, 59(10): 842-844. DOI: 10.13288/j.11-2166/r.2018.10.008. 庞莉, 葛信国. 浅析中医肿瘤学"带瘤生存"理念[J]. 中医杂志, 2018, 59(10): 842-844. DOI: 10.13288/j.11-2166/r.2018.10.008.
[58]	LIU Y, DENG H, CHEN Y, et al. Liu Weisheng's ideas in the syndrome differentiation-based treatment of liver cancer[J]. J Guangzhou Univ Tradit Chin Med, 2018, 35(3): 532-535. DOI: 10.13359/j.cnki.gzxbtcm.2018.03.032. 刘宇, 邓宏, 陈月, 等. 刘伟胜辨治肝癌思路[J]. 广州中医药大学学报, 2018, 35(3): 532-535. DOI: 10.13359/j.cnki.gzxbtcm.2018.03.032.
[59]	WANG R, HU HY. Discussion on the application potential of miRNA acupuncture to regulate tumor immunosuppression microenvironment[J]. China Mod Doct, 2021, 59(2): 187-192. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS202102065.htm 王睿, 胡海燕. 基于miRNA针灸调控肿瘤免疫抑制微环境的应用潜力探讨[J]. 中国现代医生, 2021, 59(2): 187-192. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS202102065.htm
[60]	YAMASHITA Y, YOSHIDA Y, KURIHARA T, et al. Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: Repeat hepatectomy versus salvage living donor liver transplantation[J]. Liver Transpl, 2015, 21(7): 961-968. DOI: 10.1002/lt.24111.
[61]	HE J, ZHANG DW, ZHANG YW, et al. Clinical effect of compound Kushen injection in preventing posthepatectomy recurrence in patients with primary liver cancer[J]. Chin Tradit Patent Med, 2018, 40(1): 243-244. DOI: 10.3969/j.issn.1001-1528.2018.01.055. 何津, 张大为, 张跃伟, 等. 复方苦参注射液预防原发性肝癌患者肝切除术后复发的临床观察[J]. 中成药, 2018, 40(1): 243-244. DOI: 10.3969/j.issn.1001-1528.2018.01.055.
[62]	ZHONG C, HU ML, HUANG JH, et al. Clinical effect of spleen-invigorating and blood stasis-removing TCM therapy combined with transarterial chemoembolization in treatment of postoperative recurrence of liver cancer[J]. J New Chin Med, 2016, 48(5): 208-210. DOI: 10.13457/j.cnki.jncm.2016.05.080. 钟崇, 胡明利, 黄俊海, 等. 健脾化瘀法中药联合TACE治疗肝癌术后复发临床研究[J]. 新中医, 2016, 48(5): 208-210. DOI: 10.13457/j.cnki.jncm.2016.05.080.
[63]	YANG JB, LI HJ. Effects of matrine and oxymatrine matrine on proliferation and apoptosis of hepatocellular carcinoma cells[J]. Chin J Clin Pharmacol, 2018, 34(9): 1067-1069. DOI: 10.13699/j.cnki.1001-6821.2018.09.017. 杨静波, 李宏杰. 苦参碱和氧化苦参碱对肝癌细胞增殖和凋亡的影响[J]. 中国临床药理学杂志, 2018, 34(9): 1067-1069. DOI: 10.13699/j.cnki.1001-6821.2018.09.017.
[64]	SUN C, WU MJ, JIANG ZQ, et al. Effective components 2-hydroxyl group-3-tectoquinone of Herba Hedyotis inducing liver cancer cells apoptosis by IL-6/STAT3 signaling pathway[J]. China J Tradit Chin Med Pharma, 2018, 33(12): 5346-5350. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201812018.htm 孙超, 吴铭杰, 江泽群, 等. 白花蛇舌草有效成分2-羟基-3-甲基蒽醌通过IL-6/STAT3信号通路诱导肝癌细胞凋亡作用机制[J]. 中华中医药杂志, 2018, 33(12): 5346-5350. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201812018.htm